{"id":"NCT02346240","sponsor":"UCB Biopharma S.P.R.L.","briefTitle":"Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-11","primaryCompletion":"2016-03-22","completion":"2018-12-17","firstPosted":"2015-01-26","resultsPosted":"2018-07-18","lastUpdate":"2021-07-16"},"enrollment":559,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis","Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870","CZP"]},{"type":"BIOLOGICAL","name":"Etanercept","otherNames":["Enbrel","ETN"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"CZP 200 mg","type":"EXPERIMENTAL"},{"label":"CZP 400 mg","type":"EXPERIMENTAL"},{"label":"Etanercept","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Proportion of Subjects Who Achieve a Psoriasis Activity and Severity Index (PASI75) Response at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo Q2W (RS)","deltaMin":5,"sd":null},{"arm":"Etanercept (RS)","deltaMin":53.3,"sd":null},{"arm":"CZP 200 mg Q2W (RS)","deltaMin":61.3,"sd":null},{"arm":"CZP 400 mg Q2W (RS)","deltaMin":66.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG003","p":null},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG003","p":"=0.0152"},{"comp":"OG001 vs OG002","p":"=0.1523"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":70,"countries":["United States","Bulgaria","Czechia","France","Germany","Hungary","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["29660425","34192387","32531798"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":128},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Hypertension","Viral upper respiratory tract infection","Arthralgia"]}}